<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01852175</url>
  </required_header>
  <id_info>
    <org_study_id>UFJ 2011-143</org_study_id>
    <nct_id>NCT01852175</nct_id>
  </id_info>
  <brief_title>Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease</brief_title>
  <official_title>A head-to Head Comparison of the Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently, two P2Y12 receptor inhibitors have been approved for clinical use: prasugrel and
      ticagrelor. Both prasugrel and ticagrelor have shown to be associated with more potent
      antiplatelet effects compared with clopidogrel and are associated with an improved net
      clinical benefit. However, to date there are limited head-to-head comparisons of these two
      new agents.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dual antiplatelet therapy consisting of aspirin and clopidogrel is the cornerstone of
      treatment for prevention of thrombotic events in patients with coronary artery disease (CAD)
      undergoing percutaneous coronary intervention (PCI). However, there are a considerable number
      of patients who continue to have recurrent ischemic events despite this treatment regimen.
      These observations underscore the need for more potent antiplatelet therapies. Recently, two
      P2Y12 receptor inhibitors have been approved for clinical use: prasugrel and ticagrelor. Both
      prasugrel and ticagrelor have shown to be associated with more potent antiplatelet effects
      compared with clopidogrel. These more favorable pharmacodynamic effects translate into
      reduced ischemic event rates, at the expense of an increased risk of bleeding in patients
      with acute coronary syndromes. Overall, these drugs are associated with an improved net
      clinical benefit. These findings from large-scale clinical investigations have led to
      approval of prasugrel and ticagrelor. However, to date there are limited head-to-head
      comparisons of these two new agents.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP)</measure>
    <time_frame>1 week</time_frame>
    <description>The primary end-point of the study was the comparison in the platelet reactivity index (PRI%) determined by vasodilator-stimulated phosphoprotein (VASP) at 1 week between prasugrel and ticagrelor.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)</measure>
    <time_frame>2 hours</time_frame>
    <description>A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 2 hours after loading dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)</measure>
    <time_frame>24 hours</time_frame>
    <description>A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 24 hours after loading dose.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 60mg loading dose and 10 mg maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ticagrelor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>Prasugrel 60mg loading dose and 10mg maintenance dose</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Effient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor</intervention_name>
    <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
    <arm_group_label>Ticagrelor</arm_group_label>
    <other_name>Brillinta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with known coronary artery disease

          -  On maintenance treatment with aspirin (81 mg per day) and clopidogrel (75 mg per day)
             for at least 1-month as per standard of care.

          -  Age between 18 and 74 years old.

        Exclusion Criteria:

          -  History of stroke, transient ischemic attack or intracranial bleeding.

          -  Known allergies to aspirin, prasugrel, ticagrelor, or clopidogrel.

          -  Weight &lt;60kg

          -  On treatment with oral anticoagulation (coumarin derivate, dabigatran).

          -  Hemoglobin&lt;10 gm/dL

          -  Platelet count &lt;80x106/mL

          -  Active bleeding or hemodynamic instability.

          -  Creatinine Clearance &lt;30 mL/minute.

          -  Baseline ALT &gt;2.5 times the upper limit of normal.

          -  Patients with sick sinus syndrome (SSS) or high degree AV block without pacemaker
             protection.

          -  Drugs interfering with 2C19 metabolism (to avoid interaction with clopidogrel): ,
             fluconazole (Diflucan), ketoconazole (Nizoral), voriconazole (VFEND), etravirine
             (Intelence), felbamate (Felbatol), fluoxetine (Prozac, Serafem, Symbyax), fluvoxamine
             (Luvox), and ticlopidine (Ticlid).

          -  Drugs interfering CYP3A4 metabolism (to avoid interaction with Ticagrelor):
             Ketoconazole, itraconazole, voriconazole, clarithromycin, nefazodone, ritonavir,
             saquinavir, nelfinavir, indinavir, atazanavir, and telithromizycin.

          -  Pregnant females*. *Women of childbearing age must use reliable birth control (i.e.
             oral contraceptives) while participating in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominick Angiolillo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2013</study_first_submitted>
  <study_first_submitted_qc>May 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2013</study_first_posted>
  <results_first_submitted>May 4, 2015</results_first_submitted>
  <results_first_submitted_qc>May 26, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2015</results_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Dual antiplatelet therapy</keyword>
  <keyword>prasugrel</keyword>
  <keyword>ticagrelor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between December 2011 to June 2014 patients were screened at the outpatient cardiology clinics, UF Health, University of Florida, Jacksonville.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Prasugrel</title>
          <description>Prasugrel 60mg loading dose and 10 mg maintenance dose</description>
        </group>
        <group group_id="P2">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="55"/>
                <participants group_id="P2" count="55"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prasugrel</title>
          <description>Prasugrel 60mg loading dose and 10 mg maintenance dose</description>
        </group>
        <group group_id="B2">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="55"/>
            <count group_id="B2" value="55"/>
            <count group_id="B3" value="110"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="110"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP)</title>
        <description>The primary end-point of the study was the comparison in the platelet reactivity index (PRI%) determined by vasodilator-stimulated phosphoprotein (VASP) at 1 week between prasugrel and ticagrelor.</description>
        <time_frame>1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 60mg loading dose and 10 mg maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity by Vasodilator-stimulated Phosphoprotein (VASP)</title>
          <description>The primary end-point of the study was the comparison in the platelet reactivity index (PRI%) determined by vasodilator-stimulated phosphoprotein (VASP) at 1 week between prasugrel and ticagrelor.</description>
          <units>PRI%</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.1" spread="2.5"/>
                    <measurement group_id="O2" value="32.6" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)</title>
        <description>A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 2 hours after loading dose.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 60mg loading dose and 10 mg maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)</title>
          <description>A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 2 hours after loading dose.</description>
          <units>PRI%</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="2.7"/>
                    <measurement group_id="O2" value="15.6" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)</title>
        <description>A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 24 hours after loading dose.</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prasugrel</title>
            <description>Prasugrel 60mg loading dose and 10 mg maintenance dose</description>
          </group>
          <group group_id="O2">
            <title>Ticagrelor</title>
            <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Measured by Vasodilator-stimulated Phosphoprotein (VASP)</title>
          <description>A secondary outcome was the comparison between groups of platelet reactivity index (PRI) measured by vasodilator-stimulated phosphoprotein (VASP) at 24 hours after loading dose.</description>
          <units>PRI%</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" spread="2.2"/>
                    <measurement group_id="O2" value="26.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 week</time_frame>
      <desc>Adverse events, including bleeding, bradyarrhythmias, and dyspnea, defined according to previously reported criteria were recorded</desc>
      <group_list>
        <group group_id="E1">
          <title>Prasugrel</title>
          <description>Prasugrel 60mg loading dose and 10 mg maintenance dose</description>
        </group>
        <group group_id="E2">
          <title>Ticagrelor</title>
          <description>Ticagrelor 180mg loading dose and 90mg bid maintenance dose</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <description>Dyspnea resolved spontaneously within 24 hours</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dominick J. Angiolillo, MD, PhD-Associate Professor of Medicine Director, Cardiovascular Research</name_or_title>
      <organization>University of Florida College of Medicine-Jacksonville</organization>
      <phone>+1-904-244-3005</phone>
      <email>dominick.angiolillo@jax.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

